CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins

Positive
AI Analysis

Summary

Moderna announced a $2 billion convertible senior notes offering to fund oncology business expansion and debt repayment. AstraZeneca-Amgen and Biokin reported Phase 3 trial wins.

Importance:6/10
Sentiment:
0.30
offeringconvertible notesoncologyPhase 3
Related Companies

Read the original article

Published by Endpoints News on August 27, 2026 2:59 PM

Read Original